Loading stock data…
TScan Therapeutics (TCRX)
$0.98
Market Closed
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TScan Therapeutics, Inc. in the Healthcare sector is trading at $0.98 with a market capitalization of $59M. Wall Street consensus targets $6.00 (4 analysts), implying a +513.8% move over the next 12 months. The stock is currently near its 52-week low of $0.82, remaining 21.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +513.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $982,000↓ | $2.57M↑ | $2.51M↓ | $3.08M↑ | $2.17M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$29.14M↓ | -$23.86M↑ | -$37.05M↑ | -$38.65M↓ | -$36.25M |
| Net Income | -$28.67M↓ | -$22.98M↑ | -$35.71M↑ | -$36.95M↓ | -$34.13M |
Peer Comparison
JNJUNHPFE
Fundamentals
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-128.25%
Volume
Today's trading volume
-
Recent News
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The […]
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
TScan Therapeutics, Inc. (NASDAQ:TCRX) is among the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX). With over 80% of analysts holding a “Buy” rating, the stock is projected to have a 455.56% potential upside based on the consensus price target. […]
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?